A Study of the Long-term Efficacy and Safety of a Calcipotriol Hydrate/ Betamethasone Dipropionate Ester Fixed Dose Combination Product in Patients with Psoriasis Vulgaris

DOI Web Site
  • Imafuku Shinichi
    Department of Dermatology, Faculty of Medicine, Fukuoka University Fukuoka Topical-therapy Survey Study Group for Psoriasis
  • Kusuhara Masahiro
    Kusuhara Dermatology Clinic Fukuoka Topical-therapy Survey Study Group for Psoriasis
  • Kokuba Hisashi
    Sakurazaka Dermatology Clinic Fukuoka Topical-therapy Survey Study Group for Psoriasis
  • Kobayashi Junichi
    Kobayashi Dermatology Clinic Fukuoka Topical-therapy Survey Study Group for Psoriasis
  • Takahara Masakazu
    Takahara Dermatology Clinic Fukuoka Topical-therapy Survey Study Group for Psoriasis
  • Hino Ryosuke
    Hino Dermatology Clinic Fukuoka Topical-therapy Survey Study Group for Psoriasis
  • Fumimori Takeaki
    Fumimori Dermatology Clinic Fukuoka Topical-therapy Survey Study Group for Psoriasis
  • Masuyuki Kouichi
    Masuyuki Dermatology Clinic Fukuoka Topical-therapy Survey Study Group for Psoriasis
  • Yasumoto Shinichiro
    Yasumoto Dermatology Clinic Fukuoka Topical-therapy Survey Study Group for Psoriasis
  • Yano Ichiro
    Yano Dermatology and Urology Clinic Fukuoka Topical-therapy Survey Study Group for Psoriasis

Bibliographic Information

Other Title
  • 尋常性乾癬患者に対するカルシポトリオール水和物/ベタメタゾンジプロピオン酸エステル軟膏の長期有効性および安全性の検討
  • ジンジョウセイカンセンカンジャ ニ タイスル カルシポトリオール スイワブツ/ベタメタゾンジプロピオンサン エステル ナンコウ ノ チョウキ ユウコウセイ オヨビ アンゼンセイ ノ ケントウ

Search this article

Abstract

<p>Objective: To assess the effectiveness and safety of long-term treatment with calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination (Dovobet®, Cal/BDP) ointment in patients with plaque psoriasis in the actual clinical setting.</p><p>Study methods: In patients 20 years of age or older who had psoriatic lesions involving the trunk and/or four limbs, Cal/BDP ointment was applied once daily. After at least four weeks of treatment, those who achieved remission were switched to maintenance therapy. If a relapse/recurrence was noted during the maintenance therapy period, the patient resumed the use of Cal/BDP ointment and continued with this treatment for one year.</p><p>Results: After four weeks of treatment, significant improvements were observed in the percentage change in the modified Psoriasis Area and Severity Index (m-PASI) scores, Physician's Global Assessment (PGA) scores, and Dermatology Life Quality Index (DLQI) scores; these improvement effects were maintained for one year. None of the patients experienced severe deterioration of atrophia cutis, peripheral vasodilatation or erythema, and no serious adverse events were noted.</p><p>Conclusions: Our findings suggested that long-term treatment with Cal/BDP ointment is useful in the actual clinical setting and it has a favorable tolerability profile.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top